Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
1. Introduction

Vaccines save millions of human lives. They increase the lifespan of our pets and reduce the loss of livestock. Traditionally, vaccines were based on attenuated or inactivated pathogens, or in some cases bacterial toxins. Advances in molecular biology now allow for the generation of subunit vaccines that express one or a few of the pathogens’ antigens that induce protective immune responses. Most viral and bacterial infections can be prevented by sufficiently high titers of neutralizing antibodies, which are elicited by viral surface antigens, such as the glycoprotein of rabies virus, the hemagglutinin of influenza virus, or the envelope protein of human immunodeficiency virus (HIV). For other pathogens such as those that are highly variable and thereby escape neutralization, cellular immune responses in form of CD8+ T cells may need to be elicited to prevent clinically symptomatic infections. Although unlike neutralizing antibodies CD8+ T cells fail to provide sterilizing immunity, they can rapidly clear infected cells and thereby block the spread of pathogens and ensuing disease.

CD8+ T cells come in different varieties.1 Upon activation, CD8+ T cells expand and assume effector functions. Most effector cells, which in general produce the antiviral cytokine interferon (IFN)-gamma and lytic enzymes such as perforin and granzyme B that allow for lysis of infected cells, die once the infection is cleared. A fraction differentiates into effector or central memory cells. Effector memory cells, which are longer-lived than effector cells although their numbers gradually decline, circulate through the periphery. They can rapidly assume effector functions although their proliferative capacity is limited. Central memory cells reside in lymphatic tissues. They require reactivation and expansion before they commence effector functions. Unlike effector or effector memory cells, their proliferative capacity is high and they persist through cytokine-driven cell renewal for the lifespan of an individual. Central memory cells in general produce interleukin (IL)-2 but not IFN-gamma or lytic enzymes. Which type of CD8+ T cell response is most suited to protect against an infection remains debated and most likely depends on the type of invading pathogen. For example, infections of mice with lymphocytic choriomeningitis virus can be prevented by central memory CD8+ T cells,2 whereas chronic infections of rhesus macaques with simian immunodeficiency virus (SIV) can be averted by effector memory CD8+ T cells.3 The nature of vaccine-induced immune responses is largely dictated by the type of vaccine carrier. Protein vaccines and most viral vector vaccines, with the exception of vectors based on cytomegaloviruses (CMV), can induce antibodies including
neutralizing antibodies to foreign antigens. Viral vectors that are rapidly cleared, such as those based on poxviruses or most ribonucleic acid (RNA) viruses, for example, recombinant influenza or rabies virus vectors, induce sustained central memory CD8+ T cell responses. Vectors that persist, such as those derived from CMV or adenoviruses, maintain more activated effector or effector memory CD8+ T cell responses. Adenoviral vectors persist at low levels and therefore, unlike CMV vectors, induce both sustained effector-like and central memory T cell responses.

This chapter described some basic characteristics of adenoviruses and vectors based on adenoviruses and their performance as vaccine carriers. Vaccine carriers based on adenoviruses can be designed to retain the ability to replicate or they can be rendered replication-defective upon deletion of gene segments needed for viral reproduction. Numerous serotypes of adenoviruses have been isolated from humans, nonhuman primates, and other species, which allow for generation of vectors that can be used sequentially for prime-boosting or for immunizations against different pathogens. Preexisting neutralizing antibodies to adenoviruses, which are commonly found in humans to many of the human serotypes, can impair the immunogenicity of adenoviral vectors; this can be circumvented by using vaccines based on rare human serotypes or adenoviruses isolated from other species such as chimpanzees. Unless used at excessively high doses, adenoviral vectors are well tolerated. They induce exceptionally potent and sustained B and CD8+ T cell responses to foreign antigens encoded by a transgene. Adenoviral vectors thus provide a highly suitable platform as vaccine carriers for numerous pathogens.

2. Characteristics of Adenoviruses

Adenoviruses are members of the Adenoviridae family. They are nonenveloped viruses with a double-stranded genome ranging from 25 to 48 kilobases (kb). Adenoviruses infect numerous species, including mammals, birds, and even frogs. They are subdivided into five genera depending on their target species. Human adenoviruses, which belong to the genus Mastadenovirus, are divided into seven families (A–G) and then further into 57 distinct serotypes (HAdV-1–57). Chimpanzee adenoviruses, which have been vectored for gene transfer, are grouped within human adenoviruses.

The adenovirus genome encodes from both deoxyribonucleic acid (DNA) strands a number of early and late gene products. Products of three of the four early domains, that is, E1, E2, and E4, are essential for viral replication, whereas products of E3, which are antiapoptotic or allow the virus to escape immunosurveillance, are nonessential. The late genes L1–L5 encode the icosahedral viral capsid composed of the major proteins hexon, penton, and fiber and minor proteins IIIa, VI, VIII, and IX. Hexon, the most abundant viral protein, has a conserved stalk and a head domain with several highly variable loops, which serve as targets of virus-neutralizing antibodies. Different serotypes of adenoviruses of the same family mainly differ in the sequence of these variable loops. Fiber binds the viral receptor, which for most adenoviruses is the Coxsackie adenovirus receptor (CAR), whereas others bind to CD46. Coxsackie adenovirus receptor, a type I membrane protein, is expressed on
endothelial and epithelial cells; it is not expressed on antigen-presenting cells such as dendritic cells or macrophages. CD46, an inhibitory complement receptor, is ubiquitously expressed. It also serves as receptor for measles virus and human herpes virus-6. Penton, which anchors fiber into the viral capsid, contains an arginyl-glycyl-aspartic acid (RGD) sequence, which binds to integrins and together with CAR facilitates the virus’ entry into its target cells.

Adenoviruses spread mainly by aerosols. Most cause upper respiratory diseases, conjunctivitis, tonsillitis, and ear infections. Adenovirus 40 and 41 infections are associated with gastroenteritis. In general, adenoviruses cause mild disease although severe and even fatal infections can occur in immunocompromised individuals, and on rare occasions in healthy individuals. After infection, humans shed adenoviruses in the feces for a few days whereas nonhuman primates such as chimpanzees shed viruses for very long periods of time. Adenoviruses persist at low levels in activated T cells; they can be recovered for years after infection from lymphatic tissues.

A live attenuated vaccine is available for human adenoviruses 4 and 7; it is used by the United States (US) Army for immunization of recruits.

3. Characteristics and Construction of Adenovirus Vectors

Adenoviruses have been constructed as replication-competent or replication-defective vectors. Replication-competent vectors used in a nontarget species are in fact replication-defective whereas E1-deleted replication-defective vectors can replicate to some degree in cells with transcription machineries that substitute for the deleted E1 gene products. Foreign sequences of up to 1.8 kb can be incorporated into the adenovirus genome with no deletions. Incorporation of longer sequences interferes with packaging and viral rescue. The packaging size can be increased by deletion of the E3 domain. E3 only–deleted adenovirus vectors remain replication-competent and such vectors are used as vaccine carriers. Deletions of E1, E2, or E4 render the vector replication-defective and the deleted gene products have to be provided in trans during vector production. Most vaccine vectors used to date are deleted in E1, which allows for insertion of approximately 4 kb of foreign sequences. Some are also deleted in E3, which increases the packaging capacity to about 7.5 kb. Further deletions of E4, which encodes polypeptides that affect host cell proliferation and survival and provide for nuclear export of RNA, have been explored. Additional deletion of E4 reduces the synthesis of adenoviral proteins; this in turn may reduce the stimulation of T cell response to adenoviral antigens. Originally, E1-deleted adenovirus vectors were constructed by homologous recombination in a packaging cell line that provides E1 in trans. Currently, adenoviruses are constructed from viral molecular clones by ligating a transgene expression cassette directly into the deleted E1 domain. The bacterial clone upon linearization is then transfected into the packaging cell line for viral rescue. Several packaging cell lines are available. HEK 293 cells carry the 5' gene region of HAdV-5 virus. They are suited for rescue of E1-deleted HAdV-5 vectors as well as for some of the family
E simian adenoviruses (SAdV) that are being explored as vaccine carriers. Homologous recombination between the adenovirus sequences within HEK 293 cells and the E1-deleted vector can lead to outgrowth of replication-competent viruses; this is not a problem for SAdV vectors grown on HEK 293 cells because sequence differences between the E1-flanking regions of HAdV-5 and SAdV viruses prevent homologous recombination. PER.C6 cells offer an alternative; they only carry the E1 domain of HAdV-5, which reduces the chance of insertion of E1 into the genome of HAdV-5 vectors. For other serotypes, packaging cells have to be constructed typically by stable E1 transfection of a cell line that is readily infected with adenoviruses.

Upon transfection of packaging cells with a recombinant molecular clone of adenovirus, viral plaques typically become visible after 7–10 days. Virus once expanded in packaging cells is then purified. For small-scale production, vectors are purified by CsCl gradient centrifugation, whereas for large-scale production chromatographic separation is more suited. The virus particle (vp) content of purified vectors is determined by spectrophotometry. Content of infectious virus particles (IU) is measured by plaque assays by staining for hexon or by reverse transcription polymerase chain reaction methods. Although the level of transgene product expression depends on IU, adenovirus vectors are dosed according to vp, which determines the toxicity of a preparation. The vp to IU ratios vary and are typically 5:1–400:1. Vectors with higher vp to IU ratios tend to perform poorly.

Depending on the diluent, adenovirus vectors are stable for several days at room temperature and for several months if kept on ice. Highly concentrated adenovirus vectors can be lyophilized with minimal loss in titers. Adenovirus vectors become unstable at low pH, which may pose problems for shipment in dry ice because CO₂ seeping into the vials may lower the pH, causing loss of viral titers.

Transgene product expression by adenoviral vectors is influenced by a number of parameters. In our hands, HAdV-5 vectors express higher levels of their transgene compared with HAdV-26 or family E chimpanzee-origin adenovirus vectors. A chimeric vector based on a CD46 binding chimpanzee vector was shown to express lower levels of transgene products compared with HAdV-5 vectors or a CAR-binding chimpanzee origin adenovirus vector. E1- versus E1- and E3-deleted HAdV-5 or chimpanzee-origin vectors had comparable expression whereas further deletions in E4 reduced expression. The length of the transgene product also affected levels of protein expression; longer transgenes resulted in reduced expression. The promoter regulating transgene expression was shown to influence both the magnitude and the kinetics of protein expression. The orientation of the transgene expression cassette within E1 or E3 significantly influences protein expression. We attempted to produce dual-expression adenoviral vectors, which carried one cassette in the deleted E1 domain and the other in the deleted E3 domain. Although we were able to generate stable vectors that expressed both transgene products, vectors that shared regulatory sequences within both expression cassettes were unstable, presumably owing to excision of large fragments of the genome upon homologous recombination.
4. Preexisting Immunity to Antigen of Adenoviruses

Infections with adenoviruses are common and most humans carry T cells and binding and neutralizing antibodies to adenoviruses. Neutralizing antibodies directed mainly against the adenovirus hexon are serotype-specific whereas other antibodies or T cells, which are directed to multiple antigens, including those that are highly conserved between adenovirus serotypes and even families, are highly cross-reactive. Seroconversion happens early in life. A study in Northern China showed that newborns compared with toddlers commonly have higher titers of antibodies to HAdV-2 and -5, which presumably reflects transmission of antibodies from their mothers. Infants aged 6–12 months tend to have low titers, which then steadily increase. A study conducted in India showed that neutralizing antibodies to HAdV-5 virus are slightly higher in infants aged 1–6 months than aged 7–12 months. Titers then steadily increase until adulthood. A study conducted in North America, South America, Sub-Saharan Africa, and Southeast Asia showed low seroprevalence rates in infants (up to age 6 months) to HAdV-26 and HAdV-35 virus. Children had high prevalence rates of antibodies to HAdV-5 and HAdV-26, although titers to HAdV-26 tended to be lower than those to HAdV-5. Prevalence of neutralizing antibodies in human adults varies depending on the serotype and geographic region. For example, neutralizing antibodies to common serotypes such as HAdV-5 are found in about 40% of individuals residing in the US and in up to 90% of those living in Sub-Saharan Africa. The prevalence of neutralizing antibodies to HAdV-26, which was initially described as a rare serotype, is low in the US and Europe but high in most African countries. Seroprevalence rates to HAdV-48 were shown to be high only in Africa but low in the US and Asia. HAdV-35 appeared to be a truly rare serotype; less than 20% of sera from children or adults independent of their geographic localization were able to neutralize this virus. Because adenoviruses are species-specific, most humans lack antibodies to those that infect other species, although this depends on the serotype as well as potential contact with the infected species. For examples, we described antibodies to three different chimpanzee adenoviruses (SAdV-23, SAdV-24, and SAdV-25) that were virtually absent in sera from humans residing in the US but that could be detected in up to 20% of individuals from Sub-Saharan Africa. We assumed that this reflected close contact between humans and chimpanzees in Sub-Saharan Africa, where hunting and eating monkeys is common. We subsequently conducted a study in Brazil and again found slightly enhanced prevalence rates of neutralizing antibodies to chimpanzee adenoviruses in humans residing in Brazil; this was especially pronounced in cohorts from Amazonia. Testing of New World monkeys from Brazil showed the presence of neutralizing antibodies to chimpanzee adenoviruses in nearly all sera of common marmosets, which suggested spillover of these viruses from monkeys into the human population. The same viruses tested against sera from different regions in China showed low prevalence rates for high-titer antibodies, although sera with low titers (≤1:40) were found in up to 20% of adults. Another study measured the prevalence rate of neutralizing antibodies in Caucasians residing in the US or Europe against a large panel of chimpanzee adenoviruses of family B, C, and E. The prevalence rate for the chimpanzee-origin adenoviruses with titers greater than 1:200 was in 5% of
sera with the exception of SAdV-3-neutralizing antibodies, which was found in about 10% of sera. One of the viruses, CAdV-63, was tested for neutralization by sera from Kenyan children. Sera with high titers of CAdV-63 neutralizing antibodies were rare (approximately 0.5%) whereas low titers were common (17.5%).

Preexisting neutralizing antibodies to adenovirus cause rapid uptake of the virions by cells of the reticuloendothelial system. They also lead to activation of complement. Specific neutralizing antibodies prevent cell transduction by adenoviruses and transcription and translation of the transgene product. This results in a reduction of the vaccine antigen and diminishes the vectors’ ability to stimulate adaptive immune responses while paradoxically increasing innate responses. The latter presumably reflects that neutralizing antibodies target the vectors to Fc-receptor–positive cells. Binding antibodies or preexisting T cell responses to antigens of adenovirus do not appear to have a major effect on transgene product-specific B or T cell responses. The effect of preexisting neutralizing antibodies can be circumvented by increasing the vaccine dose; this is problematic in humans because, depending on titers of neutralizing antibodies, increases by 100- to 1000-fold are required, which would likely result in unacceptable toxicity. Alternatively, adenovirus vectors could be combined with another vaccine modality such as a DNA vaccine or a poxvirus vector in a so-called prime-boost regimen. Although this is known to increase transgene product-specific immune responses markedly, it also increases the cost and complexity of a vaccine. Repeated use of the same adenovirus vector has been tested to augment immune responses; this is relatively ineffective because neutralizing antibodies induced by the first vaccine dose impair uptake of repeat doses. Loss of transduction in the presence of preexisting neutralizing antibodies can be circumvented by coating viruses with polyethylene glycol or hydrophilic polymers, or encapsidating them into microparticles. It is not yet known whether these approaches also rescue adaptive immune responses to the transgene product. It is also possible to swap variable loops of the hexon of common human serotypes with those of rare human serotypes. We used a straightforward approach by developing vectors that typically fail to infect humans, such as those derived from nonhuman primates. By now a large number of vectors have been isolated from chimpanzees. They are phylogenetically grouped within human serotypes; their molecular organization, receptor usage, and growth characteristics are similar to those of human serotypes. Antibodies to human serotypes of adenoviruses fail to cross-react with chimpanzee-derived adenoviruses. Most important, as already mentioned, neutralizing antibodies to chimpanzee adenoviruses are only rarely found in humans. Prevalence rates of such antibodies are slightly increased in Africa, presumably owing to closer contact with infected chimpanzees. Chimpanzee adenovirus vectors are thus highly suited as vaccine carriers for use in humans.

5. **Innate Immune Responses to Adenovirus Vectors**

Adenoviruses and adenovirus vectors stimulate potent innate immune responses that cause dose-limiting toxicity. Innate responses, which lead to the release of proinflammatory cytokines and chemokines such as type I IFN, IL-6, IL-12, Regulated
on Activation, Normal T cell Expressed and Secreted, macrophage inflammatory protein-1β, IFN-gamma–induced protein (IP)-10, and others, are typically triggered through recognition of pathogen-associated molecular patterns by cellular pathogen recognition receptors located on the cell surface, on endosomes, or within the cytoplasm. Several motifs present on adenovirus vectors are recognized by innate sensors. The RGD motif on penton activates the nuclear factor-kappa light chain enhancer of activated B cells pathway, which triggers an inflammatory reaction. The double-stranded adenovirus genome is recognized by Toll-like receptor (TLR)-9, one of the endosomal sensors. Adenovirus vectors appear to be recognized by additional TLRs because innate responses are diminished in cells lacking TIR domain–containing adapter-inducing IFN-beta, which serves as an adaptor to TLR-4 and -3. The adenovirus genome further activates retinoic acid–inducible gene-1, another intracellular sensor of double-stranded DNA.

Adenoviruses applied to the airways interact with surfactant, which appears to block inflammatory responses, presumably by causing opsonization of the virus particles. High doses of adenovirus vectors further activate the complement system through interactions between fiber knob with blood Factor IX and C4 binding protein. These interactions increase inflammatory responses. Adenovirus vectors are sequestered by preexisting neutralizing antibodies; for unknown reasons, this interaction increases inflammatory responses to the vectors.

The potency of innate immune responses partly depends on the vector serotype. For example, in mice, some of the chimpanzee-derived adenovirus vectors were shown to induce more potent type I IFN responses compared with HAdV-5 vectors. This may relate to the frequency of CpG motifs, which tend to be lower in genomes of HAdV-5 (2168 CG motifs) and HAdV-26 (2206 CG motifs) viruses than in those of chimpanzee-origin adenoviruses (approximately 2400–2700 CG motifs). Whether more intense inflammatory reactions in mice translate into heightened toxicity in humans remains to be tested.

6. Humoral Immune Responses to Adenoviral Vectors

Adenoviral vectors induce potent B cell responses to the capsid antigens of the vector and to foreign transgene products. The latter allow for the use of adenovirus vectors as prophylactic vaccines to infections, which can be prevented by neutralizing antibodies. The advantages of adenovirus vectors for delivery of antigens from other pathogens for induction of protective antibody responses are numerous because they interact with innate sensor drive maturation of antigen-presenting cells and do not require addition of adjuvants. E1-deleted adenoviral vectors are safe at immunogenic doses. They can be given through multiple routes including intranasal, intramuscular, and oral, provided vectors are encapsidated. Similar to wild-type adenoviruses, E1-deleted adenovirus vectors persist in activated T cells and induce sustained antibody responses. Adenoviruses use the host cell machinery for posttranslational modifications of antigens so that viral antigens are presented in their native form unless their structure depends on co-interactions with other antigens. We compared the magnitude
of transgene product-specific antibody responses to two chimpanzee-derived adenovirus vectors, both of which are family E members, with those induced by vectors derived from HAdV5, a family C member, and HAdV26, a family D member.\textsuperscript{45} Vectors expressed the rabies virus glycoprotein as the transgene product. The HAdV-5 vector induced markedly higher rabies virus-specific antibody responses compared with the other vectors.

E3-deleted HAdV-5 vectors expressing the rabies virus glycoprotein have been licensed for immunization of wildlife such as foxes or skunks.\textsuperscript{77} Neither of these species supports replication of HAdV-5 virus, so that in its intended target species the vaccine is replication-defective. E1-deleted adenovirus vectors based on simian serotypes also expressing the rabies virus glycoprotein are under development for human immunization.\textsuperscript{33} These vectors are highly immunogenic and induce protective titters of rabies virus–neutralizing antibodies in nonhuman primates after a single low dose ($10^9$ vp) given intramuscularly before challenge.\textsuperscript{78} Antibody titters and protective immunity were shown to be sustained for at least 2 years. Ebola virus in the winter and spring of 2014 caused an outbreak in Guinea, which by fall of the same year had spread to Liberia and Sierra Leone with isolated cases imported to Europe and the US. The World Health Organization estimated that without improved interventions, the virus would continue to spread and potentially infect up to a million individuals by 2015.\textsuperscript{79} Others voiced concern about viral mutation that may allow Ebola virus to be transmitted by aerosols, even further increasing infection rates. One of the first Ebola vaccines that underwent testing in humans was based on an E1-deleted HAdV-5 vector expressing the glycoproteins of Zaire and Sudan Ebola species.\textsuperscript{80} The vaccine, which had been shown to protect nonhuman primates against Ebola virus infection,\textsuperscript{81} was found to be safe at $2 \times 10^{10}$ vp per dose and human subjects developed specific T and B cell responses. Because of concerns about preexisting HAdV-5 neutralizing antibodies,\textsuperscript{82} which tend to be prevalent and robust in African human populations, a second set of vectors based on chimpanzee serotype 3 was constructed.\textsuperscript{83} This vaccine is currently undergoing testing in human volunteers. Provided the vaccine is immunogenic and safe, it may then be used under an investigational new drug application in consenting individuals at high risk of contracting the virus. One potential setback of this Ebola vaccine is that although humoral responses to the viral glycoprotein developed rapidly in nonhuman primates, antibody titters were not sustained, but rather declined to baseline within less than a year. This could potentially be addressed by a booster immunization with an adenovirus vector based on a different serotype or an unrelated vaccine prototype such as a poxvirus vector.

A plethora of adenovirus vectors based on human and simian serotypes have been tested preclinically for induction of protective antibody responses to numerous pathogens including hepatitis B virus,\textsuperscript{84} Dengue virus,\textsuperscript{85} \textit{Severe acute respiratory syndrome} coronavirus,\textsuperscript{86} rotavirus,\textsuperscript{87} respiratory syncytial virus,\textsuperscript{88} rabies virus,\textsuperscript{33,77} herpes simplex virus type 2,\textsuperscript{89} Hantaan virus,\textsuperscript{90} influenza virus,\textsuperscript{91} and plasmodium vivax.\textsuperscript{92} Results consistently showed that the vectors induced potent antibody responses dominated by isotypes linked to type 1 T helper cell responses upon systemic immunization whereas mucosal injections also led to local immunoglobulin A production.\textsuperscript{93}
7. Cellular Immune Responses to Adenoviral Vectors

Although neutralizing antibodies are the primary correlate of protection against most pathogens for some of the more complex viruses, intracellular bacteria, or protozoa, protection can be provided by cellular immune responses that achieve accelerated clearance of infected cells. By the same token, chronic viral infections or cancer cells are best combated with vaccine-induced CD8+ T cell responses. Adenoviruses acquired by natural infections induce CD4+ and CD8+ T cell responses to a number of viral proteins. Such T cells can be found in most human adults. They cross-react between different adenovirus serotypes including those derived from chimpanzee-origin adenoviruses. Adenovirus-specific CD4+ T cells were found to be monofunctional; they largely belong to the memory subset. In contrast, adenovirus-specific CD8+ T cells are more polyfunctional. They are highly activated and are phenotypically mainly grouped into effector/effector memory subsets. This may reflect repeated exposures to different serotypes of adenoviruses or internal reactivations of CD8+ T cells by persisting viruses. Adenoviral vectors induce remarkably high transgene product-specific CD8+ T cell responses and, at least in mice, only modest CD4+ T cell responses. Induction of T cells is triggered by cross-presentation of antigen. Transgene product-specific CD8+ T cells similar to those induced by natural infections to the adenovirus antigens are polyfunctional, and because of the vectors’ persistence, a large proportion remains activated. Nevertheless, because levels of persistence are low, adenovirus-induced T cells in part transition into the memory pool, which allows for increased responses after booster immunizations.

We compared the magnitude of transgene product-specific CD8+ T cell responses to HAdV-5, HAdV-26, and chimpanzee-derived adenovirus vectors SAdV-24 and SAdV-25. In mice, responses were largely comparable. Others compared T cell responses to different human and chimpanzee serotypes in mice and rhesus macaques. In both species, human serotypes adenoviruses such as HAdV-5 and -6 based on family C induced higher CD8+ T cell responses compared with those from family D, such as HAdV-26 or HAdV-24. Adenovirus vectors based on family B, such as HAdV-35 and HAdV34, both of which use CD46 rather than CAR for cell entry, were the least immunogenic. Similar trends were seen for chimpanzee-origin adenovirus vectors; those from group C, such as SAdV-3, SAdV-20, or SAdV-11, tended to be more immunogenic than those of group E, such as SAdV-4 or -5, whereas the one group B virus, SAdV-30, was the least immunogenic. Nevertheless, some of the family E–derived vectors were as immunogenic as or even more so than some of the family C vectors.

Large numbers of different adenovirus vectors have undergone preclinical testing as T cell–inducing vaccines for a variety of pathogens, including HIV-1/SIV, hepatitis C virus (HCV), Trypanosome cruzii, Mycobacterium tuberculosis, dengue virus, human CMV, influenza A virus, Rift valley fever virus, and Epstein Barr virus. Results showed that adenovirus vectors induced exceptionally potent and sustained CD8+ T cell responses in animals that were higher than those induced by other recombinant vaccines such as DNA vaccines or poxvirus vectors. T cell responses induced by an adenovirus vector can be enhanced by prime boost-regimens using serologically distinct adenovirus vectors or other vaccine platforms for priming or boosting.
8. **Clinical Experience with Vaccines Based on Adenoviral Vector**

Early-stage safety studies have been conducted with several human- as well as chimpanzee-derived adenovirus vectors expressing antigens of HIV-1,\textsuperscript{58} M. tuberculosis,\textsuperscript{105} Plasmodium falciparum,\textsuperscript{106} Ebola virus,\textsuperscript{80} influenza A virus,\textsuperscript{107} and HCV.\textsuperscript{108} Results showed that toxicity was dose-related and unaffected by preexisting neutralizing antibodies to the vectors.\textsuperscript{109,110} At high doses of $10^{11}$ vp, individuals mainly experienced mild to moderate flulike symptoms with fever, myalgia, fatigue, and headache. Injection-site reactions such as erythema and local pain were seen regardless of vector dose. Repeated injections of the same vector resulted in decreased systemic reactions upon sequential immunizations.\textsuperscript{111} Vaccinated individuals did not develop significant changes in blood values. Overall, the vaccines were well tolerated. Analyses of vaccine-induced immune responses showed that in a dose-dependent manner, vaccine recipients developed T and B cells to the transgene product. They also had increases in immune responses to antigens of the adenoviral vector.

The first large-scale phase IIb trial for an adenoviral vector vaccine, the STEP trial, was conducted by Merck with HAdV-5 vectors expressing Gag, Pol, and Nef of HIV-1 clade B for induction of T cells. Individuals from North or South America, the Caribbean, or Australia at high risk for HIV-1 acquisition received three injections of $5 \times 10^{10}$ vp of the vaccine or placebo on day 1 and weeks 4 and 26. The trial was designed to enroll 1500 individuals with HAdV-5–specific neutralizing antibody titers less than 1:200 at baseline and 1500 individuals with titers greater than 1:200. As expected, the vaccine elicited potent CD8\textsuperscript{+} T cell responses that were slightly attenuated in individuals with high titers of preexisting neutralizing antibodies to HAdV-5. CD4\textsuperscript{+} T cell responses to HIV-1 were observed in only about a third of vaccine recipients.\textsuperscript{112} The trial was stopped prematurely after an interim analysis by the Safety Monitoring Board showed that the vaccine neither prevented HIV-1 infections nor reduced viral loads in individuals who became infected.\textsuperscript{113} A trial conducted in parallel in South Africa, the Phambili trial,\textsuperscript{114} was stopped shortly thereafter and in both trials participants were unblinded. In the STEP trial, male vaccine recipients, who were mainly homosexual and engaged in high-risk anal intercourse had increased rates of HIV-1 acquisition (49 of 941 male vaccine recipients) compared with placebo controls (33 of 922 participants). Increased acquisition was linked to high titers of HAdV-5–neutralizing antibodies at baseline as well as the lack of circumcision.\textsuperscript{115} There was no link to differences in risk behavior.\textsuperscript{115} This trend for increased HIV-1 acquisition, which was transient and waned after about 18 months,\textsuperscript{116} was not seen in the Phambili trial, which enrolled mainly heterosexual men and women. Additional studies comparing HIV-1 acquisition rates of participants in other HIV-1 trials based on vaccines other than adenoviral vectors showed that titers of neutralizing antibodies to several adenoviral serotypes did not increase HIV-1 acquisition.\textsuperscript{117} By the same token, the army failed to observe increases in HIV-1 infection rates in recruits who received the live attenuated adenovirus vaccines compared with those who did not.\textsuperscript{118} High neutralizing antibody titers to adenovirus per se or vaccination with an adenovirus thus
do not appear to increase the risk of HIV-1 infection. The mechanisms underlying the increased acquisition of HIV-1 in HAdV-5–seropositive individuals of the STEP trial have been studied extensively but remain unexplained. One possibility that has been explored is that CD4+ T cells induced by adenovirus vectors become highly susceptible to infection with HIV-1. Such T cells also express homing markers for gut mucosa. The increased presence of HIV-1 target cells at the port of viral entry could explain increased HIV-1 acquisition after vaccination with an adenoviral vector; nevertheless, it does not explain why this increased acquisition was seen only in homosexual males with high baseline titers of HAdV-5–specific neutralizing antibodies.

The next large-scale efficacy trial was again based on an HAdV-5 vector combined with DNA vaccine priming to prevent HIV-1. The DNA vaccine expressed Gag, Pol, Nef, and Env from clade A, B, and C. The HAdV-5 vectors given as mixtures expressed a gag–pol fusion protein and Env of clades A, B, and C. The HAdV-5 vector of HVTN505 differed from the vector used in the STEP trial by the additional deletion of E4 and by the inclusion of Env as a vaccine target antigen. The DNA vaccines were given three times on days 0 and weeks 4 and 8; the HAdV-5 vectors were given once on week 24. The study, conducted in the US, enrolled circumcised males and transgender women with preexisting neutralizing antibody titers to HAdV-5 below 1:18, who were at high risk for HIV-1 acquisition. A total of 1251 participants were enrolled into the vaccine arm; 1245 participants were enrolled into the placebo arm. End points were the prevention of HIV-1 acquisition or lowering of viral loads in infected vaccine recipients. An interim analysis showed that neither of these end points would be met and the trial was halted and unblinded. The vaccines did not increase HIV-1 acquisition rates. The vaccine induced HIV-1–specific CD4+ and/or CD8+ T cells in about 60% of recipients, antibodies to gp41 in all recipients, and antibodies to gp120 in about 50% of vaccine recipients. Antibodies to the V1–V2 loop, which in another, more successful HIV-1 vaccine efficacy trial had been identified as correlates of protection against viral acquisition, were detected in only about 20% of vaccine recipients. Responses rates for neutralizing antibodies were low and only tier 1 HIV-1 virus could be neutralized.

The futility of three HAdV-5 vector-based HIV-1 vaccine efficacy trials combined with the increased risk for HIV-1 acquisition in a subcohort of the STEP trial raised questions about the use of adenoviral vectors as a vaccine platform for HIV-1 in general. The initial early-phase immunogenicity trials with the STEP and HVTN505 vaccines had shown that the breadth of HIV-1–specific T cell responses was limited because T cells from most vaccinated individuals only recognized one to four epitopes of HIV-1. This limited epitope specificity was recapitulated in a small phase I trial with an HAdV-26 vaccine expressing Env. We tested chimpanzee-derived adenovirus vectors expressing HIV-1 clade B Gag in rhesus macaques, and after a single immunization the breadth of the response was also limited and most animals responded to only one or two epitopes. A boost with a serologically distinct adenovirus vectors markedly increased the breadth of the response and most animals responded after the boost to 15–30 different Gag epitopes. The restricted epitope specificity observed in the clinical trials, which carries the risk that HIV-1 may escape cellular
Adenoviral Vectors for Gene Therapy

immunosurveillance, can thus potentially be addressed by prime-boosting with two different serotypes of adenovirus vector vaccines. Also, the efficacy of the STEP and HVTN505 vaccines was limited in preclinical studies. The STEP vaccine protected rhesus macaques against challenge with the SIV/HIV chimera SHIV89.6P but provided no protection against a more stringent challenge with SIVmac239. By the same token, the HVTN505 vaccine failed to protect rhesus macaques from SIVmac251 challenges but conferred MHC class I allele-dependent protection against the less stringent SIVsmE660 challenge. Others described induction of protective immunity in rhesus macaques immunized with adenovirus vectors from other human as well as chimpanzee serotypes against SIVmac239 or SIVmac251, and the use of these alternative adenovirus vector for HIV-1 prophylaxis continues to be explored.

Other clinical efficacy trials explored HAdV-5 or CAdV-63 as carriers for malaria vaccines. An HAdV-5 vector expressing the P. falciparum circumsporozoite protein and apical membrane antigen-1 failed to protect against a controlled malaria infection whereas some protection (about 27%) was achieved when this vaccine was combined with a DNA vaccine prime. A similar level of efficacy was achieved with a CAdV-63 expressing T cell–inducing antigens of P. falciparum followed by a modified vaccinia Ankara boost.

Adenovirus vector-based vaccines for M. tuberculosis have thus far undergone only early-stage safety and immunogenicity trials. An HAdV-5 vector expressing Ag85A was shown to induce T cells in individuals who were naive to antigens of this pathogen; responses were more robust in previously BCG vaccinated trial volunteers. Immunogenicity was not affected by preexisting HAdV-5–neutralizing antibodies.

One phase I trial tested HAdV-6 and CAdV-3 vectors expressing the NS protein of HCV. Both vectors induced HCV-specific T cell responses that cross-reacted between heterologous HCV strains. Responses to either vaccine were polyfunctional and sustained. Responses were boosted when the two vectors were used sequentially.

References

1. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004;78:5535–45.
2. Bachmann MF, Wolint P, Schwarz K, Oxenius A. Recall proliferation potential of memory CD8+ T cells and antiviral protection. J Immunol 2005;175:4677–85.
3. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell Vaccine. Nature 2011;473:523–7.
4. Hansen SG, Piatak Jr M, Ventura AB, Hughes CM, Gilbride RM, Ford JC, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013;502:100–4.
5. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, Zhou D, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007;110:1916–23.
6. http://www.vmri.hu/~harrach/AdVtaxlong.htm.
7. Wold WS, Gooding LR. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 1991;184:1–8.
8. Roberts MM, White JL, Grütter MG, Burnett RM. Three-dimensional structure of the adenovirus major coat protein hexon. *Science* 1986;232:1148–51.
9. Pichla-Gollon SL, Drink M, Zhou X, Xue F, Rux JJ, Gao GP, et al. Structure-based identification of a major neutralizing site in an adenovirus hexon. *J Virol* 2007;81:1680–9.
10. Crawford-Miksza L, Schnurr DP. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. *J Virol* 1996;70:1836–44.
11. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. *J Immunol* 2005;174:7179–85.
12. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science* 1997;275:1320–3.
13. Segerman A, Atkinson JP, Marttila M, Dennerquist V, Vadell G, Arnb erg N. Adenovirus type 11 uses CD46 as a cellular receptor. *J Virol* 2003;77:9183–91.
14. Gaggar A, Shayakhetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. *Nat Med* 2003;9:1408–12.
15. Dörig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). *Cell* 1993;75:295–305.
16. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lu sso P. CD46 is a cellular receptor for human herpesvirus 6. *Cell* 1999;99:817–27.
17. Mathias P, Wickham T, Moore M, Nemerow G. Multiple adenovirus serotypes use alpha v integrins for infection. *J Virol* 1994;68:6811–4.
18. Pereira HG. Persistent infection by adenoviruses. *J Clin Pathol Suppl* 1972;6:39–42.
19. Hoke Jr CH, Hawksworth A, Snyder Jr CE. Initial assessment of impact of adenovirus type 4 and type 7 vaccine on febrile respiratory illness and virus transmission in military basic trainees, March 2012. *MSMR* 2012;19:2–4.
20. Marienfeld U, Haack A, Thalheimer P, Schneider-Rasp S, Brackmann HH, Poller W. ‘Autoreplication’ of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes. *Gene Ther* 1999;6:1101–13.
21. Koup RA, Lamoreaux L, Zarkowsky D, Bailler RT, King CR, Gall JG, et al. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. *J Virol* 2009;83:6318–22.
22. Thummel C, Tjian R, Grootzicker T. Construction of adenovirus expression vectors by site-directed in vivo recombination. *J Mol Appl Genet* 1982;1:435–46.
23. Zhou D, Zhou X, Bian A, Li H, Chen H, Small JC, et al. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. *Nat Protoc* 2010;5:1775–85.
24. Shaw G, Morse S, Ararat M, Graham FL. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. *FASEB J* 2002;16:869–71.
25. Zhu J, Grace M, Casale J, Chang AR, Musco ML, Bordens L. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. *Hum Gene Ther* 1999;10:113–21.
26. Lochmuller H, Jani A, Huard J, Prescott S, Simoneau M, Massie B, et al. Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1+delta E3) during multiple passages in 293 cells. *Hum Gene Ther* 1994;5:1485–91.
27. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. *Hum Gene Ther* 1998;9:1909–17.
28. Murakami P, Havenga M, Fawaz F, Vogels R, Marzio G, Pungor E, et al. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. *J Virol* 2004;78:6200–8.

29. Eglon MN, Duffy AM, O’Brien T, Strappe PM. Purification of adenoviral vectors by combined anion exchange and gel filtration chromatography. *J Gene Med* 2009;11:978–89.

30. Lee DS, Kim BM, Seol DW. Improved purification of recombinant adenoviral vector by metal affinity membrane chromatography. *Biochem Biophys Res Commun* 2009;37:640–4.

31. Dormond E, Kamen AA. Manufacturing of adenovirus vectors: production and purification of helper dependent adenovirus. *Methods Mol Biol* 2011;737:139–56.

32. Cassandra Nyberg-Hoffman C, Aguilar-Cordo E. Instability of adenoviral vectors during transport and its implication for clinical studies. *Nat Med* 1999;5:955–7.

33. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. *J Virol* 2002;76:2667–75.

34. Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. *J Immunol* 2003;170:1416–22.

35. Tatsis N, Blejer A, Lasaro MO, Hensley SE, Cun A, Tesema L, et al. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. *Mol Ther* 2007;15:608–17.

36. Chen P, Tian J, Kovesdi I, Bruder JT. Promoters influence the kinetics of transgene expression following adenovector gene delivery. *J Gene Med* 2008;10:123–31.

37. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. *J Gen Virol* 1997;78(Pt 7):1653–61.

38. Small JC, Kurupati RK, Zhou X, Bian A, Chi E, Li Y, et al. Construction and characterization of E1- and E3-deleted adenovirus vectors expressing two antigens from two separate expression cassettes. *Hum Gene Ther* 2014;25:328–38.

39. Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HC, Betts MR. Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. *Vaccine* 2010;28:1932–41.

40. Yu B, Wang Z, Dong J, Wang C, Gu L, Sun C, et al. A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011. *Virol J* 2012;9:287.

41. Appaiahgari MB, Pandey RM, Vrati S. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. *Clin Vaccine Immunol* 2007;14:1053–5.

42. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. *Vaccine* 2011;29:5203–9.

43. Farina SF1, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, et al. Replication-defective vector based on a chimpanzee adenovirus. *J Virol* 2001;75:11603–13.

44. Xiang Z1, Li Y, Cun A, Yang W, Ellenberg S, Switzer WM, et al. Chimpanzee adenovirus antibodies in humans, Sub-Saharan Africa. *Emerg Infect Dis* 2006;12:1596–9.

45. Chen H, Xiang ZQ, Li Y, Kurupati RK, Jia B, Bian A, et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. *J Virol* 2010;84:10522–32.

46. Ersching J, Hernandez MI, Cezarotto FS, Ferreira JD, Martins AB, Switzer WM, et al. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. *Virology* 2010;407:1–6.
47. Jian L, Zhao Q, Zhang S, Huang W, Xiong Y, Zhou X, et al. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China. *Arch Virol* 2014;**159**:465–70.

48. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. *Sci Transl Med* 2012;**4**:115ra2.

49. Cichon G, Boeckh-Herwig S, Schmidt HH, Wehnes E, Muller T, Pring-Akerblom P, et al. Complement activation by recombinant adenoviruses. *Gene Ther* 2001;**8**:1794–800.

50. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. *J Virol* 2007;**81**:6594–6604.

51. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. *Gene Ther* 2005;**12**:427–36.

52. Varnavski AN, Zhang Y, Schnell M, Tazelaar J, Louboutin JP, Yu QC, et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. *J Virol* 2002;**76**:5711–9.

53. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. *J Virol* 2003;**77**:6305–13.

54. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, Ertl HC. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. *J Immunol* 2003;**171**:6774–9.

55. Tatsis N, Lin SW, Harris-McCoy K, Garber DA, Feinberg MB, Ertl HC. Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. *Virology* 2007;**367**:156–67.

56. Graham BS, Enama ME, Nason MC, Gordon IJ, Peel SA, Ledgerwood JE, et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. *PLoS One* 2013;**8**:e59340.

57. Bart PA, Huang Y, Karuna ST, Chappuis S, Gaillard J, Kochar N, et al. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. *J Clin Invest* 2014;**124**:4843–56.

58. Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. *J Infect Dis* 2010;**201**:132–41.

59. Casimiro DR, et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. *J Virol* 2003;**77**:7663–8.

60. O’Riordan CR, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. *Hum Gene Ther* 1999;**10**:1349–58.

61. Fisher KD, Stallwood W, Ulbrich K, Mautner V, Seymour LW. Protection and retargeting of adenovirus using a multifunctional hydrophilic polymer. *Mol Ther* 2000;**18**:57.

62. Sailaja G, HogenEsch H, North A, Hays J, Mittal SK. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. *Gene Ther* 2002;**9**:1722–9.
63. Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, et al. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). *J Infect Dis* 2014;210:1052–61.

64. Roy S, Sandhu A, Medina A, Clawson DS, Wilson JM. Adenoviruses in fecal samples from asymptomatic rhesus macaques, United States. *Emerg Infect Dis* 2012;18:1081–8.

65. Rux JJ, Kuser PR, Burnett RM. Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. *J Virol* 2003;77:9553–66.

66. Hirschowitz EA, Weaver JD, Hidalgo GE, Doherty DE. Murine dendritic cells infected with adenovirus vectors show signs of activation. *Gene Ther* 2000;7:1112–20.

67. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. *Mol Ther* 2007;15:378–85.

68. Hartman ZC, Black EP, Amalfitano A. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. *Virology* 2007;358:357–72.

69. Hartman ZC, Kiang A, Everett RS, Serra D, Yang XY, Clay TM, et al. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. *J Virol* 2007;81:1796–812.

70. Cheng G, Zhong J, Chung J, Chisari FV. Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. *Proc Natl Acad Sci USA* 2007;104:9035–40.

71. Harrod KS, Trapnell BC, Otake K, Korfhagen TR, Whitsett JA. SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection. *Am J Physiol Lung Cell Mol Physiol* 1999;277(3 Pt 1):L580–8.

72. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. *Mol Ther* 2004;10:1140–2.

73. Shayakhmetov DM, Gaggera A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. *J Virol* 2005;79:7478–91.

74. Hensley SE, Cun AS, Giles-Davis W, Li Y, Xiang Z, Lasaro MO, et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. *Mol Ther* 2007;15:393–403.

75. Hensley SE, Giles-Davis W, McCoy KC, Weninger W, Ertl HC. Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. *J Immunol* 2005;175:6032–41.

76. Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. *Virology* May 1, 1996;219:220–7.

77. Lutze-Wallace C, Wandeler A, Prevec L, Sidhu M, Sapp T, Armstrong J. Characterization of a human adenovirus 5: rabies glycoprotein recombinant vaccine reisolated from orally vaccinated skunks. *Biologicals* 1995;23:271–7.

78. Xiang ZQ, Greenberg L, Ertl HC, Rupprecht CE. Protection of non-human primates against rabies with an adenovirus recombinant vaccine. *Virology* 2014;450–451:243–9.

79. Meltzer MI, Atkins CY, Santibanez S, Knust B, Petersen BW, Ervin ED, et al. Estimating the future number of cases in the Ebola epidemic – Liberia and Sierra Leone, 2014–2015. *MMWR Surveill Summ* 2014;63:1–14.

80. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, et al. VRC 205 Study Team. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. *Vaccine* 2010;29:304–13.
81. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006;3:e177.

82. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011;85:4222–33.

83. http://www.fiercevaccines.com/story/nih-ebola-vaccine-trial-will-begin-september/2014-08-01.

84. Hung PP, Morin JE, Lubeck MD, Barton JE, Molnar-Kimber KL, Mason BB, et al. Expression of HBV surface antigen or HIV envelope protein using recombinant adenovirus vectors. Nat Immun Cell Growth Regul 1988;7:135–43.

85. Khanam S, Pilankatta R, Khanna N, Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009;27:6011–21.

86. Shim BS, Stadler K, Nguyen HH, Yun CH, Kim DW, Chang J, et al. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Virol J 2012;9:215.

87. Zhou H, Guo L, Wang M, Qu J, Zhao Z, Wang J, et al. Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. Virol J 2011;8:3.

88. Sharma A, Wendland R, Sung B, Wu W, Grunwald T, Worgall S. Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection. Vaccine 2014;32:5761–8.

89. Gallichan WS, Rosenthal KL. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995;13:1589–95.

90. Li K, Li PY, Wu XA, Zhang L, Liu ZY, Yu L, et al. Induction of Hantaan virus-specific immune responses in C57BL/6 mice by immunization with a modified recombinant adenovirus containing the chimeric gene, GcS0.7. Int J Mol Med 2013;32:709–16.

91. Kim EH, Park HJ, Han GY, Song MK, Pereboev A, Hong JS, et al. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice. J Virol 2014;88:9693–703.

92. Xiang Z, Ertl HC. Induction of mucosal immunity with a replication-defective adenoviral recombinant. Vaccine 1999;17:2003–8.

93. Prasad SA, Norbury CC, Chen W, Bennink JR, Yewdell JW. Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J Virol 2009;83:2623–31.

94. Miyahira Y, Takashima Y, Kobayashi S, Matsumoto Y, Takeuchi T, Ohyanagi-Hara M, et al. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 2005;73:7356–65.
97. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006;74:4634–43.

98. Radosevic K, Wieland CW, Rodriguez A, Weverling G, Mintardjo R, Gillissen G, et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007;75:4105–15.

99. Gao G, Wang Q, Dai Z, Calcedo R, Sun X, Li G, et al. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. Hum Gene Ther 2008;19:927–36.

100. Zhong J, Khanna R. Ad-gBCMVpoly: a novel chimeric vaccine strategy for human cytomegalovirus-associated diseases. J Clin Virol 2009;46(Suppl 4):S68–72.

101. DiMenna L, Latimer B, Parzych E, Haut LH, Töpfer K, Abdulla S, et al. Augmentation of primary influenza A virus-specific CD8+ T cell responses in aged mice through blockade of an immunoinhibitory pathway. J Immunol 2010;184:5475–84.

102. Lambe T, Carey JB, Li Y, Spencer AJ, van Laarhoven A, Mullarkey CE, et al. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci Rep 2013;3:1443.

103. Wardimwe GM, Lorenzo G, Lopez-Gil E, Reyes-Sandoval A, Cottingham MG, Spencer AJ, et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J 2013;10:349.

104. Leskowitz R, Fogg MH, Zhou XY, Kaur A, Silveira EL, Villinger F, et al. Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques. J Virol 2014;88:4721–35.

105. Smailil F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, Zganiacz A, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013;5:205ra134.

106. Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One 2013;8:e57726.

107. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005;23:1029–36.

108. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained a T cell responses to HCV in man. Sci Transl Med 2012;4:115ra1.

109. Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, et al. For the Merck V520-018/HIV Vaccine Trials Network 050 Study Team. Safety and immunogenicity of the MRKAd5 gag HIV type 1 vaccine in a Worldwide phase 1 study of healthy adults. AIDS Res Hum Retroviruses 2011;27:557–67.

110. Hayton EJ, Rose A, Ibrahimusa U, Del Sorbo M, Capone S, Crook A, et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase 1 trial. PLoS One 2014;9:e101591.

111. Harro CD, Robertson MN, Lally MA, O’Neill LD, Edupuganti S, Goepfert PA, et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 2009;25:103–14.
112. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372:1894–905.

113. Buchbinder SP, Mehotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881–93.

114. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. HVTN 503/Phambili study team. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis 2014;14:388–96.

115. Koblin BA, Mayer KH, Noonan E, Wang CY, Marmor M, Sanchez J, et al. Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study. J Acquir Immune Defic Syndr 2012;60:405–13.

116. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Step/HVTN 504 Study Team. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 2012;206:258–66.

117. Stephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH. Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J Infect Dis 2012;205:1806–10.

118. http://www.niaid.nih.gov/topics/HIV/AIDS/Research/vaccines/Pages/adenovirusPlatforms.aspx.

119. Hu H, Eller MA, Zafar S, Zhou Y, Gu M, Wei Z, et al. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proc Natl Acad Sci USA 2014;111:13439–44.

120. http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HVTN505April2013.aspx.

121. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. MOPH-TA VEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209–20.

122. Yates NL, Liao HX, Fong Y, Decamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 2014;19:6(228):228ra39.

123. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010;5:e9015.

124. Lasaro MO, Haut LH, Zhou X, Xiang Z, Zhou D, Li Y, et al. Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques. Mol Ther 2011;19:417–26.

125. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331–5.

126. Reynolds MR, Weiler AM, Piaskowski SM, Piatak Jr M, Robertson HT, Allison DB, et al. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 2012;30:4465–75.

127. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim SY, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011;3:81ra36.
128. Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009;457:87–91.

129. Tamminga C, Sedegah M, Maiolatesi S, Fedders C, Reyes S, Reyes A, et al. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PiCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum Vaccin Immunother 2013;9:2165–77.

130. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013;8:e55571.

131. Ewer KJ, O’Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013;4:2836.